China’s vaccine landscape is shifting after local biotech Xiamen Innovax Biotech unveiled the country’s first domestically ...

Merck withdrew its $11 billion annual sales target for Gardasil given the "uncertain timing of an economic recovery in China," the company's CFO Caroline Litchfield said during the call on Tuesday.

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Merck issued guidance for 2025 that lags consensus amid struggles in China with Gardasil Merck's stock tumbled 11.8% Tuesday, putting it on track for its biggest one-day selloff in almost 17 years ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck , known as MSD outside of the United States and Canada, today announced that the National Medical Products Administration (NMPA) of China approved GARDASIL ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.